Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Host – hepatitis C viral interactions: The role of genetics
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Hepatic CD141+IFNλ+ DC subset: One against all?
The yin and yang of evasion and immune activation in HCC
The inflammasome in liver disease
Obesity, inflammation, and liver cancer
T. Vescovo, G. Refolo, G. Vitagliano, G.M. Fimia, M. Piacentini 
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Bridget A. Robinson, Timothy J. Nice  Immunity 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Gianluca Tell, Carlo Vascotto, Claudio Tiribelli  Journal of Hepatology 
Volume 57, Issue 1, Pages 6-8 (July 2012)
Agustín Albillos, Margaret Lario, Melchor Álvarez-Mon 
Hepatitis C-associated B-cell non-Hodgkin lymphomas
Volume 49, Issue 5, Pages (November 2008)
Immigration and viral hepatitis
Hepatitis B and C virus-related carcinogenesis
Regulatory T-cell directed therapies in liver diseases
Allogeneic hematopoietic cell transplant in HCV-infected patients
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Volume 59, Issue 3, Pages (September 2013)
Inflammation and portal hypertension – The undiscovered country
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
From immunosuppression to tolerance
Regulatory T-cell directed therapies in liver diseases
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Volume 53, Issue 4, Pages (October 2010)
Volume 68, Issue 3, Pages (March 2018)
The yin and yang of evasion and immune activation in HCC
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 45, Issue 4, Pages (October 2006)
Ribavirin ante portas: Uptake transporters into hepatocytes dissected
Autophagy in the liver Journal of Hepatology
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Mona Malz, Federico Pinna, Peter Schirmacher, Kai Breuhahn 
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Percy A. Knolle, Robert Thimme  Gastroenterology 
Hepatitis B and C virus-related carcinogenesis
Tumor Promotion via Injury- and Death-Induced Inflammation
Cannabinoid signaling and liver therapeutics
Volume 63, Issue 2, Pages (August 2015)
Senescence in chronic liver disease: Is the future in aging?
Volume 50, Issue 4, Pages (April 2009)
Volume 61, Issue 1, Pages S79-S90 (November 2014)
miR-122 – A key factor and therapeutic target in liver disease
Immigration and viral hepatitis
Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva 
Macrophage heterogeneity in liver injury and fibrosis
Silvia Affò, Ramón Bataller  Journal of Hepatology 
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Chimeric mouse model of hepatitis B virus infection
Foxa1 and Foxa2 regulate bile duct development in mice
Hepatitis E virus: Infection beyond the liver?
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Philippe Metz, Antje Reuter, Silke Bender, Ralf Bartenschlager 
Host – hepatitis C viral interactions: The role of genetics
Volume 61, Issue 2, Pages (August 2014)
Platelets arrive at the scene of fibrosis……studies
Presentation transcript:

The role of Kupffer cells in hepatitis B and hepatitis C virus infections  Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman  Journal of Hepatology  Volume 61, Issue 3, Pages 660-671 (September 2014) DOI: 10.1016/j.jhep.2014.04.026 Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 1 The role of KC in anti-viral immunity and tissue damage during HBV and HCV infection. Exposure of KC to HBV or HCV will lead to direct activation of KC that, together with infected hepatocytes, release cytokines and chemokines, which are responsible for the attraction of other leukocytes. Activation of infiltrating immune cells leads to further production of cytokines that indirectly activate KC. The secreted cytokines may inhibit viral replication (green text). However, persistent exposure of KC to HBV or HCV will continuously activate KC leading to the ongoing release of cytokines and chemokines attracting and activating more leukocytes. Likewise, continuous activation of infiltrating leukocytes leads to ongoing production of cytokines that indirectly activate KC. Some of the cytokines secreted are pro-fibrotic factors. Additionally, KC and other immune cells are able to induce apoptosis of infected as well as uninfected hepatocytes, and release cytokines, which drive compensatory proliferation of hepatocytes. The ongoing cycles of hepatocyte death and regeneration increase the chances of spontaneous mutations and DNA damage, which may eventually result in HCC (red text). Journal of Hepatology 2014 61, 660-671DOI: (10.1016/j.jhep.2014.04.026) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Role of KC in immune regulation and viral persistence during HBV and HCV infection. Exposure of KC to HBV or HCV will lead to their activation and the release of anti-inflammatory cytokines and expression of inhibitory molecules. Combined with impaired antigen presentation by KC, these regulatory mechanisms will interfere with KC function and that of other immune cells, frustrating anti-viral immunity. Journal of Hepatology 2014 61, 660-671DOI: (10.1016/j.jhep.2014.04.026) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2014 61, 660-671DOI: (10. 1016/j. jhep. 2014. 04 Copyright © 2014 European Association for the Study of the Liver Terms and Conditions